Ori Biotech
Adam Wieschhaus is the current director at Ori Biotech. Adam has previously worked at Isolere Bio, Kytopen, Slingshot Biosciences, Torus Biosystems, Vestaron Corporation, Northpond Ventures, IsoPlexis (NASDAQ: ISO), Inflammatix, Inc., and Ori Biotech.
Adam Wieschhaus studied pharmacology at Tufts University School of Medicine and earned their Ph.D. from the University of Illinois College of Medicine. Adam also holds a B.S. in biochemistry and molecular biology from The University of Georgia. In addition, they are a Chartered Financial Analyst (CFA) and is certified by the Financial Industry Regulatory Authority (FINRA) in Series 7, 86, 87, and 63.
This person is not in the org chart
This person is not in any offices
Ori Biotech
Ori Biotech is a London- and New Jersey-based innovator in CGT manufacturing that has developed a proprietary, bespoke and flexible manufacturing platform, which enables patient access to a new generation of personalized, life-saving treatments.